跳至主要内容
临床试验/JPRN-jRCTs061190040
JPRN-jRCTs061190040已完成2 期

Protective effect with Glu-Cer intake against adverse skin event of chemoradiotherapy

Fujiwara Kazunori0 个研究点目标入组 7 人开始时间: 2020年3月16日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
7

研究概览

简要总结

It is possible that oral administration of ceramide improves the moisturizing function, and if a moisturizing effect is obtained, it may be expected to suppress the onset of skin disorders. On the other hand, hifu002 did not improve the moisturizing effect despite oral administration. Although we do not know why the moisturizing effect was not improved, the development of severe skin damage suggest that there may be some relationship between the moisturizing effect and the degree of skin damage.

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 ot applicable(—)
性别
All

入选标准

  • Origin of the cancer: maxillary, oral cavity, pharynx, larynx, cervical esophagus
  • Recieve chemoradiation against head and neck cancer
  • Over 20 years old
  • Enable to take a medicine orally
  • Patient with bone marrow, and/or hepatic, and/or renal insufficiency within 14 days before starting of a trial
  • Sign a consent form on one's own

排除标准

  • Konjac allergy
  • Prominent symptom at the site of a skin test
  • Patient who had chronic skin disorder like collagen diseases and take medication regularly
  • Remain under other scrutiny, or within 3 months after finishing other clinical trial
  • Asthma patients
  • Take antihistamine medicine
  • At risk of becoming pregnant and breast-feeding woman

研究者

发起方
Fujiwara Kazunori

相似试验